Menu Search
Equities

Pfizer Ltd

PFIZER:NSI

Pfizer Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)5,225.65
  • Today's Change97.75 / 1.91%
  • Shares traded12.15k
  • 1 Year change+27.14%
  • Beta0.4471
Data delayed at least 15 minutes, as of Nov 22 2024 10:20 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy2
Outperform0
Hold1
Sell0
Strong Sell0

Share price forecast in INR

The 3 analysts offering 12 month price targets for Pfizer Ltd have a median target of 6,375.00, with a high estimate of 7,175.00 and a low estimate of 5,300.00. The median estimate represents a 21.65% increase from the last price of 5,240.60.
High36.9%7,175.00
Med21.6%6,375.00
Low1.1%5,300.00

Dividends

In 2024, Pfizer Ltd reported a dividend of 35.00 INR, equaling last years dividend. The 3 analysts covering the company expect dividends of 44.67 INR for the upcoming fiscal year, an increase of 27.62%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in INR

On May 17, 2024, earnings of 22.33 per share.
The next earnings announcement is expected on May 15, 2025.
Average growth rate-11.56%
Pfizer Ltd reported annual 2024 earnings of 118.77 per share on May 17, 2024.
Average growth rate+2.45%
More ▼

Revenue history & estimates in INR

Pfizer Limited had 2nd quarter 2025 revenues of 5.89bn. This missed the 6.23bn consensus estimate of the 2 analysts following the company. This was 10.77% above the prior year's 2nd quarter results.
Average growth rate+0.66%
Pfizer Limited had revenues for the full year 2024 of 21.93bn. This was 9.55% below the prior year's results.
Average growth rate+1.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.